taladegib
Phase 1Small molecule
taladegib is one of 6 small molecule programs targeting Drug Interactions. It is currently in Phase 1.
1
Indications
6
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Drug Interactions
#DrugCompanyPhaseTrials
1Ofev
Boehringer IngelheimPhase 1
Esbriet
LLegacy Health System
Phase 1
DWP16001
Daewoong Pharmaceutical Co. LTD.Phase 1
Onglyza
AstraZenecaPreclinical
Drug Cocktail
Eli LillyPhase 1
taladegib
EEndeavor Biomedicines, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Drug Interactions1 trial
Idiopathic Pulmonary Fibrosis1 trial
Gastroesophageal Junction Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for taladegib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- EEndeavor Biomedicines, Inc.